Potential of protein kinase inhibitors for treating herpesvirus-associated disease

Trends in Microbiology

Volumn 21, Issue 6, 2013, Pages 286-295

  Li, Renfeng ^a   Hayward, S Diane ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antiviral drug development; Herpesvirus; Phosphorylation; Protein kinase; Protein kinase inhibitor

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ALISERTIB; AURORA A KINASE; BRUTON TYROSINE KINASE; CIDOFOVIR; CYCLIN DEPENDENT KINASE; CYTARABINE; DASATINIB; EPHRIN RECEPTOR A2; EVEROLIMUS; FLAVOPIRIDOL; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; IBRUTINIB; IMATINIB; OLOMOUCINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; PURVALANOL A; RAPAMYCIN; ROSCOVITINE; SEMAXANIB; SORAFENIB; TRIFLURIDINE; TROMANTADINE; UNINDEXED DRUG; VALACICLOVIR; VASCULOTROPIN RECEPTOR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; B CELL LYMPHOMA; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DISEASE MODEL; EPSTEIN BARR VIRUS; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GRAFT REJECTION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; KIDNEY CANCER; KIDNEY CARCINOMA; LYMPHOMA; MASS SPECTROMETRY; NASOPHARYNX CARCINOMA; NEOPLASM; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SOLID TUMOR; VARICELLA ZOSTER VIRUS; VIRUS CARCINOGENESIS; VIRUS ENTRY; VIRUS INHIBITION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS RELEASE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HUMANS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME; VIRUS REPLICATION;

HERPESVIRIDAE;

EID: 84878463182     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2013.03.005     Document Type: Review

References (98)

1. Arvin A., et al. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis 2007, Cambridge University Press.
2. Morgan D.O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 1997, 13:261-291.
3. Knockaert M., et al. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 23:417-425.
4. Deshpande A., et al. Cyclins and cdks in development and cancer: a perspective. Oncogene 2005, 24:2909-2915.
5. Bresnahan W.A., et al. Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. Virology 1997, 231:239-247.
6. Sanchez V., et al. Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production. J. Virol. 2004, 78:11219-11232.
7. Sanchez V., Spector D.H. Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles. J. Virol. 2006, 80:5886-5896.
8. Schang L.M., et al. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J. Virol. 1998, 72:5626-5637.
9. Schang L.M., et al. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. J. Virol. 2002, 76:7874-7882.
10. Schang L.M., et al. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. J. Virol. 2000, 74:2107-2120.
11. Schang L.M., et al. Explant-induced reactivation of herpes simplex virus occurs in neurons expressing nuclear cdk2 and cdk4. J. Virol. 2002, 76:7724-7735.
12. Holcakova J., et al. The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties. Antivir. Chem. Chemother. 2010, 20:133-142.
13. Kudoh A., et al. Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication. J. Virol. 2004, 78:104-115.
14. Taylor S.L., et al. Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus. J. Virol. 2004, 78:2853-2862.
15. Moffat J.F., et al. Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis. Biochim. Biophys. Acta 2004, 1697:225-231.
16. Kang M.S., et al. Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenance. J. Virol. 2011, 85:2859-2868.
17. Habran L., et al. Varicella-zoster virus IE63 protein phosphorylation by roscovitine-sensitive cyclin-dependent kinases modulates its cellular localization and activity. J. Biol. Chem. 2005, 280:29135-29143.
18. Hoessel R., et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1999, 1:60-67.
19. Hertel L., et al. Viral and cell cycle-regulated kinases in cytomegalovirus-induced pseudomitosis and replication. PLoS Pathog. 2007, 3:e6.
20. Schang L.M., et al. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir. Chem. Chemother. 2006, 17:293-320.
21. Hsieh W.S., et al. Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin. Cancer Res. 2009, 15:1435-1442.
22. Pasquale E.B. Eph receptor signalling casts a wide net on cell behaviour. Nat. Rev. Mol. Cell Biol. 2005, 6:462-475.
23. Hahn A.S., et al. The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma-associated herpesvirus. Nat. Med. 2012, 18:961-966.
24. Chakraborty S., et al. Kaposi's sarcoma-associated herpesvirus interacts with EphrinA2 receptor to amplify signaling essential for productive infection. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E1163-E1172.
25. Williams L.T. Signal transduction by the platelet-derived growth factor receptor. Science 1989, 243:1564-1570.
26. Soroceanu L., et al. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 2008, 455:391-395.
27. Michaelis M., et al. The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. Cell. Mol. Life Sci. 2011, 68:1079-1090.
28. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8:579-591.
29. Koon H.B., et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 2005, 23:982-989.
30. Mohamed A.J., et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol. Rev. 2009, 228:58-73.
31. Merchant M., Longnecker R. LMP2A survival and developmental signals are transmitted through Btk-dependent and Btk-independent pathways. Virology 2001, 291:46-54.
32. Advani R.H., et al. Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 2013, 31:88-94.
33. Cai Q., et al. Kaposi's sarcoma herpesvirus upregulates Aurora A expression to promote p53 phosphorylation and ubiquitylation. PLoS Pathog. 2012, 8:e1002566.
34. Mahadevan D., et al. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 2012, 18:2210-2219.
35. Poglitsch M., et al. CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. Am. J. Transplant. 2012, 12:1458-1468.
36. Moody C.A., et al. Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. J. Virol. 2005, 79:5499-5506.
37. Cen O., Longnecker R. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma. Mol. Cancer Ther. 2011, 10:679-686.
38. Moorman N.J., Shenk T. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J. Virol. 2010, 84:5260-5269.
39. Roy D., et al. mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Res. 2013, 73:2235-2246.
40. Harper J.W., Elledge S.J. The DNA damage response: ten years after. Mol. Cell 2007, 28:739-745.
41. Lilley C.E., et al. Using or abusing: viruses and the cellular DNA damage response. Trends Microbiol. 2007, 15:119-126.
42. Terry L.J., et al. Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:3071-3076.
43. McArdle J., et al. HCMV targets the metabolic stress response through activation of AMPK whose activity is important for viral replication. PLoS Pathog. 2012, 8:e1002502.
44. McArdle J., et al. Inhibition of calmodulin-dependent kinase kinase blocks human cytomegalovirus-induced glycolytic activation and severely attenuates production of viral progeny. J. Virol. 2011, 85:705-714.
45. El-Guindy A.S., et al. Identification of constitutive phosphorylation sites on the Epstein-Barr virus ZEBRA protein. J. Biol. Chem. 2006, 281:3085-3095.
46. Sivachandran N., et al. Epstein-Barr virus nuclear antigen 1 hijacks the host kinase CK2 to disrupt PML nuclear bodies. J. Virol. 2010, 84:11113-11123.
47. Medina-Palazon C., et al. Protein kinase CK2 phosphorylation of EB2 regulates its function in the production of Epstein-Barr virus infectious viral particles. J. Virol. 2007, 81:11850-11860.
48. Smith M.C., et al. CK2 inhibitors increase the sensitivity of HSV-1 to interferon-beta. Antivir. Res. 2011, 91:259-266.
49. Kuang E., et al. Activation of p90 ribosomal S6 kinase by ORF45 of Kaposi's sarcoma-associated herpesvirus and its role in viral lytic replication. J. Virol. 2008, 82:1838-1850.
50. Woodard C., et al. Phosphorylation of the chromatin binding domain of KSHV LANA. PLoS Pathog. 2012, 8:e1002972.
51. Zapata H.J., et al. Varicella-zoster virus infection of human fibroblast cells activates the c-Jun N-terminal kinase pathway. J. Virol. 2007, 81:977-990.
52. Goswami R., et al. Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr virus. Antivir. Res. 2012, 96:296-304.
53. Karaman M.W., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
54. Gershburg E., Pagano J.S. Conserved herpesvirus protein kinases. Biochim. Biophys. Acta 2008, 1784:203-212.
55. Zhu J., et al. Protein array identification of substrates of the Epstein-Barr virus protein kinase BGLF4. J. Virol. 2009, 83:5219-5231.
56. Deruelle M.J., Favoreel H.W. Keep it in the subfamily: the conserved alphaherpesvirus US3 protein kinase. J. Gen. Virol. 2011, 92:18-30.
57. Wang X., et al. US3 protein kinase of HSV-1 cycles between the cytoplasm and nucleus and interacts with programmed cell death protein 4 (PDCD4) to block apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14632-14636.
58. Munger J., Roizman B. The US3 protein kinase of herpes simplex virus 1 mediates the posttranslational modification of BAD and prevents BAD-induced programmed cell death in the absence of other viral proteins. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10410-10415.
59. Chuluunbaatar U., et al. Constitutive mTORC1 activation by a herpesvirus Akt surrogate stimulates mRNA translation and viral replication. Genes Dev. 2010, 24:2627-2639.
60. Erazo A., et al. Varicella-zoster virus open reading frame 66 protein kinase is required for efficient viral growth in primary human corneal stromal fibroblast cells. J. Virol. 2008, 82:7653-7665.
61. Walters M.S., et al. Histone deacetylases 1 and 2 are phosphorylated at novel sites during varicella-zoster virus infection. J. Virol. 2009, 83:11502-11513.
62. Li R., et al. Conserved herpesvirus kinases target the DNA damage response pathway and TIP60 histone acetyltransferase to promote virus replication. Cell Host Microbe 2011, 10:390-400.
63. Jong J.E., et al. Kaposi's sarcoma-associated herpesvirus viral protein kinase interacts with RNA helicase a and regulates host gene expression. J. Microbiol. (Seoul, Korea) 2010, 48:206-212.
64. Chang Y.H., et al. Epstein-Barr virus BGLF4 kinase retards cellular S-phase progression and induces chromosomal abnormality. PLoS ONE 2012, 7:e39217.
65. Hume A.J., et al. Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 2008, 320:797-799.
66. Kudoh A., et al. Epstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment. J. Biol. Chem. 2005, 280:8156-8163.
67. Hwang S., et al. Conserved herpesviral kinase promotes viral persistence by inhibiting the IRF-3-mediated type I interferon response. Cell Host Microbe 2009, 5:166-178.
68. Vandevenne P., et al. The varicella-zoster virus ORF47 kinase interferes with host innate immune response by inhibiting the activation of IRF3. PLoS ONE 2011, 6:e16870.
69. Wang J.T., et al. Epstein-Barr virus BGLF4 kinase suppresses the interferon regulatory factor 3 signaling pathway. J. Virol. 2009, 83:1856-1869.
70. Lee C.P., et al. Epstein-Barr virus BGLF4 kinase induces disassembly of the nuclear lamina to facilitate virion production. J. Virol. 2008, 82:11913-11926.
71. Hamirally S., et al. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog. 2009, 5:e1000275.
72. Krosky P.M., et al. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 2003, 77:905-914.
73. Cano-Monreal G.L., et al. Herpes simplex virus 2 UL13 protein kinase disrupts nuclear lamins. Virology 2009, 392:137-147.
74. Li R., et al. SUMO binding by the Epstein-Barr virus protein kinase BGLF4 is crucial for BGLF4 function. J. Virol. 2012, 86:5412-5421.
75. Tarakanova V.L., et al. Gamma-herpesvirus kinase actively initiates a DNA damage response by inducing phosphorylation of H2AX to foster viral replication. Cell Host Microbe 2007, 1:275-286.
76. Hagemeier S.R., et al. The cellular ataxia telangiectasia-mutated kinase promotes Epstein-Barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli. J. Virol. 2012, 86:13360-13370.
77. Xiaofei E., et al. An E2F1-mediated DNA damage response contributes to the replication of human cytomegalovirus. PLoS Pathog. 2011, 7:e1001342.
78. Marty F.M., et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect. Dis. 2011, 11:284-292.
79. Manning G., et al. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
80. Nikitin P.A., et al. An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe 2010, 8:510-522.
81. Dillon P.J., et al. Tousled-like kinases modulate reactivation of gammaherpesviruses from latency. Cell Host Microbe 2013, 13:204-214.
82. Zhong J., et al. TSLP signaling network revealed by SILAC-based phosphoproteomics. Mol. Cell. Proteomics 2012, 11. M112 017764.
83. Liang Y., et al. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. mBio 2013, 4. e00558-12.
84. Zerboni L., et al. Herpes simplex virus 1 tropism for human sensory ganglion neurons in the severe combined immunodeficiency mouse model of neuropathogenesis. J. Virol. 2013, 87:2791-2802.
85. Zerboni L., et al. Aberrant infection and persistence of varicella-zoster virus in human dorsal root ganglia in vivo in the absence of glycoprotein I. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:14086-14091.
86. Chono K., et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J. Antimicrob. Chemother. 2010, 65:1733-1741.
87. Ma S.D., et al. An Epstein-Barr virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J. Virol. 2012, 86:7976-7987.
88. Smith M.S., et al. Granulocyte-colony stimulating factor reactivates human cytomegalovirus in a latently infected humanized mouse model. Cell Host Microbe 2010, 8:284-291.
89. Feng W.H., et al. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J. Virol. 2004, 78:1893-1902.
90. Fu D.X., et al. Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat. Med. 2008, 14:1118-1122.
91. Hill J.A., et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007, 84:1436-1442.
92. Kobashigawa J., et al. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transpl. Infect. Dis. 2013, 15:150-162.
93. Pope L.E., et al. The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antivir. Res. 1998, 40:85-94.
94. Schang L.M., et al. Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases. J. Virol. 1999, 73:2161-2172.
95. Rowe J., et al. Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice. Antivir. Res. 2010, 86:276-285.
96. Alekseev O., et al. Targeting host kinases for the treatment of herpes keratitis. Acta Ophthalmol. 2012, 90(Suppl.). 10.1111/j.1755-3768.2012.T112.x.
97. Johnson R.A., et al. The role of MKK1/2 kinase activity in human cytomegalovirus infection. J. Gen. Virol. 2001, 82:493-497.
98. Johnson R.A., et al. Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J. Virol. 2001, 75:6022-6032.